Needham & Company LLC Issues Positive Forecast for ICU Medical (NASDAQ:ICUI) Stock Price

ICU Medical (NASDAQ:ICUI) had its target price lifted by equities research analysts at Needham & Company LLC from $165.00 to $187.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s price objective suggests a potential upside of 12.40% from the stock’s previous close.

A number of other brokerages have also issued reports on ICUI. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Finally, KeyCorp increased their target price on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and an average target price of $186.40.

ICU Medical Stock Down 0.0%

ICUI opened at $166.37 on Friday. The company has a market cap of $4.16 billion, a PE ratio of 89.93, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. ICU Medical has a twelve month low of $107.00 and a twelve month high of $176.27. The company has a 50-day moving average price of $150.66 and a 200 day moving average price of $140.72. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. During the same period in the previous year, the firm posted $2.10 EPS. ICU Medical’s revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Sell-side analysts expect that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Several hedge funds have recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System raised its holdings in ICU Medical by 2.0% in the 4th quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after acquiring an additional 70 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of ICU Medical by 0.3% during the 1st quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock valued at $3,934,000 after acquiring an additional 90 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of ICU Medical by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock worth $803,000 after purchasing an additional 100 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after purchasing an additional 101 shares during the last quarter. Finally, Lido Advisors LLC raised its stake in shares of ICU Medical by 4.5% in the 4th quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock valued at $354,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical News Roundup

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations. ICU Medical reported adjusted EPS of $2.37, well above the $1.91 analyst consensus and up from $2.10 a year earlier. Revenue reached $547.9 million versus expectations of $533.4 million. ICU Medical Second-Quarter 2026 Results
• Positive Sentiment: Full-year guidance was raised or reaffirmed above Wall Street expectations. ICU Medical provided fiscal 2026 EPS guidance of $8.60 to $9.00, compared with the consensus estimate of $7.83. The guidance signals stronger anticipated earnings than analysts had previously modeled. Analysts Boost ICU Medical Forecasts
• Positive Sentiment: Analysts increased their price targets. Following the earnings beat and updated outlook, analysts raised their forecasts for ICUI, providing an additional catalyst for the stock and indicating improved confidence in the company’s earnings trajectory. Analyst Price-Target Changes
• Neutral Sentiment: Revenue growth remained limited. Quarterly revenue increased only 0.5% year over year, while the company reported a 2.15% net margin and 7.50% return on equity. Investors may therefore focus on whether earnings growth is sustainable and supported by stronger sales expansion. ICU Medical Q2 Key Metrics
• Negative Sentiment: Valuation remains demanding. With ICUI trading near its 52-week high at roughly 90 times earnings, the stock has limited room for execution disappointments despite the positive earnings news.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.